ABSTRACT

Aim: The goal of this research is to develop Opicapone oral disintegrating tablets. This is an oral COMT inhibitor for the treatment of pakinson's disease symptoms that are 'wearing off.' Purpose: A fast-dissolving Opicapone pill dissolves quickly in saliva, and the medicine is also available in solution or suspension form for instant absorption and activity. Materials and methods: Opicapone is the subject of the current study. Orally disintegrating tablets were made utilising a direct compression process with different superdisintegrant concentrations of Lycoat, Crosspovidone, and SSG (sodium starch glycolate).. Results and Discussion: The precompression and postcompression parameters of the formulations were assessed. We found no interactions between the pure drug (Opicapone) and the optimised formulation (Opicapone + excipients) in the drug excipient compatibility studies, indicating that there are no physical changes. The IP restrictions for post compression and post compression Parameters were verified to be met. Conclusion: The tablet with the highest concentration of Crosspovidone releases 98.13 percent of the medication within 20 minutes and follows first order kinetics. Overall, the results showed that the formulation F8 containing Crosspovidone was superior and more capable of meeting the needs of the orally disintegrating tablet. Keywords: Orally disintegrating tablet, Opicapone, Crosspovidone, Lycoat, Sodium starch glycolate, superdisintegrant
Publication date: 01/11/2022

https://ijbpas.com/pdf/2022/November/MS_IJBPAS_2022_6382.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.11.6382